|
||
Article |


Department of Pathology, and
Department of Physiology, McGill University, Montreal, Quebec, Canada H3G 1Y6
| Abstract |
|---|
|
|
|---|
Protein tyrosine phosphorylation is regulated by the two antithetic gene families, protein tyrosine kinases (PTKs)1 and protein tyrosine phosphatases (PTPs). These have been found in most signaling pathways and, in particular, in those occurring in immature as well as completely differentiated lymphoid cells involved in processes such as T cell receptor activation and secretion of cytokines by the stromal cells of the bone marrow (BM; reference 1). Protein tyrosine phosphorylation acts as a delicate switch modulating protein–protein interactions that are crucial for the immune system function. Several members of these two gene families have been directly implicated in lymphoid cell signaling. For example, the tyrosine kinases Lck, Fyn, Csk, and c-abl are essential for normal T and B cell activation and maturation (2–6). Conversely, the expression of several PTP members has been noted in lymphoid cells. Thus far, two PTPs have been directly associated with immune system functions: CD45, a receptor phosphatase, and the SH2 containing PTP, SHP-1 (7, 8). Gene targeting of the murine CD45 gene demonstrated a positive role for CD45 in thymocytes and B cell development, in part through its action on the Lck kinase (9, 10). Furthermore, mutations in the SHP-1 PTPase cause severe autoimmunity and widespread hematopoietic failure in the motheaten (me) mouse mutant, demonstrating the importance of tyrosine dephosphorylation in the proper development and maintenance of a functional immune system (11, 12).
The mammalian T cell PTP (TC-PTP) was one of the first members of the PTP gene family identified. Although originally cloned from a T cell cDNA library, it is ubiquitously expressed at all stages of mammalian development and in most embryonic and adult tissues (13, 14). Yet, TC-PTP is found in higher amounts in lymphoid cell lineages suggesting that in addition to CD45 and SHP-1, TC-PTP could play an important role in immunity. Two major forms of human TC-PTP, designated TC-PTPa and TC-PTPb, are generated by alternative splicing at the 3' end of the gene (14, 15). These two forms, also referred to as PTP-S2 and PTP-S4 (16), differ in their COOH termini with TC-PTPa containing 382 amino acids (aa) that includes a unique 6 aa COOH tail end, PRLTDT, and TC-PTPb possessing a 34 aa hydrophobic tail. Immunofluorescence studies localize the TC-PTPa form to the nucleus and the TC-PTPb form to the endoplasmic reticulum (16–19). Importantly, the TC-PTPb levels vary among cell types and mammalian species, and it is generally the least abundant of the two forms where it represents a fraction of TC-PTP message in mice (14) and in rats and humans (16).
Expression of TC-PTPb in baby hamster kidney cells demonstrated that it is associated with the particulate cellular fraction, and is inactive in an in vitro assay unless it is first subjected to limited trypsinization (20). These results were further substantiated by the work of Zander et al. (21) who reported on the differential enzymatic activities and substrate specificities of the full-length and truncated forms of the TC-PTPb enzyme in which the COOH-terminal hydrophobic region is deleted. A recent report by Kamatkar et al. (16) also supported these studies and, in addition, showed that only the TC-PTPa form can bind nonspecifically to DNA in vitro. Thus, the hydrophobic COOH-terminal portion of human TC-PTP appears to regulate substrate specificity, enzymatic activity, and subcellular localization. Tillman et al. showed that the steady state levels of murine TC-PTPa messenger RNA fluctuate in a cell cycle–specific manner, with levels remaining low in all stages of the cell cycle except in late G1 where expression increases (18). In support of a function for TC-PTP in the cell cycle, Gould et al. demonstrated that human TC-PTPb can complement, at the nonpermissive temperature, a thermosensititve mutant of the dual-specific PTP p80cdc25 in Schizosaccharomyces pombe (22).
Since the physiological substrate(s) of either form of TC-PTP remains unknown and given the potential artefactual phenotypes caused by dephosphorylation of nonspecific substrates in transfected cells, we generated null mutant mice for TC-PTP using gene targeting technology in an attempt to further characterize its function in vivo. All homozygous null TC-PTP mutant animals appeared normal for the first 2 wk, exibited severe weight loss after those 2 wk, and died by 5 wk after birth. Examination of lymphoid-derived cells indicated that TC-PTP–deficient mice displayed deficient T and B cell proliferative responses and a defect in B cell ontogeny and erythroid development in the BM. In addition, BM transfer studies demonstrated that the failure of hematopoiesis was not due to stem cell dysfunction, but rather to an inability of stromal cells to support normal hematopoiesis.
Phage Mapping and Targeting Vector Construction.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Genomic Library Screening and DNA Probe Preparation.
A
DASH IITM (Stratagene Corp., La Jolla, CA) phage genomic library derived from 129/sv mouse female kidney DNA (a gift of Dr. Janet Rossant, Mt. Sinai Hospital, Toronto, Canada) was screened using plaque hybridization techniques as previously described (23) and a 32P-labeled TC-PTP cDNA as probe. Plasmid DNA was prepared by alkali lysis and polyethylene glycol precipitation as previously described (24). DNA probes used in library screening, phage DNA mapping, and Southern and Northern hybridization analyses were obtained by restriction enzyme digestion of plasmid DNA followed by agarose gel electrophoresis and GenecleanTM (BIO/101, Vista, CA) purification of the excised DNA fragments. The DNA fragments were labeled with
-[32P]dCTP (New England Nuclear, Boston, MA) using random primers and T7 DNA polymerase (T7 Quick-PrimeTM; Pharmacia, Piscataway, NJ). Removal of unincorporated nucleotides was achieved by SephadexTM G-50 (Pharmacia) spin chromatography.
The intron/exon boundaries of genomic clones were determined by Southern mapping and DNA sequencing. Dideoxy sequencing reactions were performed using
-[35S]dATP (New England Nuclear) and SequenaseTM version 2.0 (Amersham Corp., Arlington Heights, IL) as stated in the manufacturer's instructions. The TC-PTP targeting construct as shown in Fig. 1 A was generated by subcloning, into pBluescriptTM II KS(+) (Stratagene Corp.), the neomycin (neo) resistance gene cassette flanked by TC-PTP genomic sequences. pMC1neoPolyA (Stratagene Corp.) contains a 1-kb cassette with the neomycin resistance gene under the control of the Herpes simplex thymidine kinase gene promoter. The plasmid was digested with XhoI, the overhangs were blunt ended with deoxyribonucleotides (Pharmacia) and the Klenow fragment of DNA polymerase I (New England Biolabs, Beverly, MA), and then digested with HindIII. The 1.1-kb fragment was gel purified and ligated using T4 DNA ligase (New England Biolabs) to pBluescriptTM II KS(+) that had been digested with PstI, rendered blunt ended as described above, and digested with HindIII, generating the plasmid BSNEO.
|
Embryonic Stem Cells, Electroporation, and Selection.
Techniques used were essentially as described elsewhere (25, 26). In brief, the 129/sv embryonic stem (ES) cell line J1 (27) was expanded on mitomycin C (10 µg/ml)–treated mouse embryonic (BALB/c) fibroblasts (28). DMEM (28) was supplemented with leukemia inhibitory factor at 1,000 U/ml (ESGRO; GIBCO BRL, Gaithersburg, MD). Trypsinized cells (1–2 x 107) were washed and resuspended in 1 ml of 1x PBS, mixed with 50 µg of linearized plasmid DNA, and electroporated using a gene pulser (240 V, 500 µF; Bio Rad Labs., Hercules, CA). After electroporation, ES cells were plated at a density of 1.5–3 x 105 cells/60-mm plate on BALB/c-NEOr feeders, and 24 h later, selection was applied with DMEM containing G418 (400 µg/ml powder; GIBCO BRL). 10–12 d after transfection, individual colonies were transferred to 96-well plates, expanded for freezing, and DNA extraction as described elsewhere (28).
Generation of Chimeric and Heterozygous Mice.
BALB/c blastocysts were injected with 10–15 heterozygously targeted ES cells and transferred into appropriate foster mothers. Chimeric males were mated with normal BALB/c females, and genotyping of heterozygous animals was performed by Southern blot analysis.
Southern Blotting Analysis of ES Cell and Mouse Genomic DNA.
DNA from individual ES cell colonies grown in 96-well plates and genomic DNA (10–50 µg) isolated from mouse tails or from cells of the LN, thymus, or spleen were digested to completion with 20 U of NdeI and analyzed by Southern blotting as previously described (24). Following UV cross-linking, the membrane was prehybridized and hybridized in hybridization solution (0.5 M NaH2PO4, pH 7.0, 1 mM EDTA, 7% SDS, 0.5% BSA; reference 29) in the presence of a 32P-labeled probe lying outside of the targeting vector but present in a novel restriction fragment length polymorphism (probe A, Fig. 1 A). Membranes were washed at 65°C in 2x SSC/0.1%SDS for 30 min (twice) and in 0.2x SSC/ 0.1% SDS for 30 min (twice), and were exposed to x-ray film (XAR-5; Kodak, Rochester, NY) with intensifying screens at –80°C for several days.
Northern Blotting Analysis.
RNA for northern analysis was extracted from wild-type (wt) and TC-PTP –/– spleen using the TRIzolTM reagent (GIBCO BRL) as previously described (30). 30 µg of total RNA was electrophoresed on a 1% agarose gel containing formaldehyde (24). The gel was capillary transferred onto nylon membrane (Hybond-N+TM, Amersham Corp.). A 32P-labeled DNA fragment corresponding to the entire cDNA of TC-PTP was used as a probe. Hybridization and washing conditions were performed as described for Southern analysis. After exposure, the membrane was stripped (0.5% SDS at 100°C for 20 min, twice) and reprobed with a [32P] cDNA fragment derived from rat glyceraldehyde 3-phosphate dehydrogenase gene which served as a loading control (31).
Western Blotting Analysis.
Spleen samples from wt or TC-PTP –/– mice were prepared in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% SDS, 0.25% sodium deoxycholate, 1% NP-40, and 1 mM EGTA, and supplemented with a protease inhibitor mixture, CompleteTM, Boehringer Mannheim, Indianapolis, IN). Equivalent protein amounts dissolved in SDS-PAGE sample buffer were subjected to SDS-PAGE on a 10% polyacrylamide gel. Gel was transferred onto polyvinylidene difluoride membranes by electrotransfer, and blots were processed for chemiluminescence detection as per manufacturer's recommendations (New England Nuclear, Boston, MA). Anti–TC-PTP monoclonal Ab 3E2 was used as the primary antibody (1:50 dilution of conditioned hybridoma culture media) followed by an anti–mouse IgG antibody conjugated to horseradish peroxidase (Amersham Corp.).
Flow Cytometry.
On different days after birth, mice were killed and spleen, LN, and thymus were removed for preparation of cell suspensions in HBSS (GIBCO BRL) as previously described (32). BM cell suspension was prepared by aspirating the marrow of the tibia and femur. One million cells were labeled with the appropriate reagents and fixed in 1 ml of 1% paraformaldehyde as previously described (32). Fixed samples were analyzed by a FACScan® (Becton Dickinson, San Jose, CA), and 5,000 flow cytometry events were counted per sample. A selective gate, excluding cell debris, was set by using forward light scatter.
Reagents for Flow Cytometry.
FITC-conjugated anti–mouse CD8 (clone YTS 169.4), PE-conjugated anti–mouse CD4 (L3/T4 clone YTS191.1), FITC-conjugated anti-sIgM, PE-conjugated anti–mouse B220 (CD45R, Ly5, clone RA3-6B2), PE-conjugated anti–mouse Gr1 (clone RB6-8C5, rat Ig2b
isotype; PharMingen, San Diego, CA), anti-F4/80 (gift from Dr. M.G. Baines, McGill University, Montreal, Canada), and the corresponding secondary antibodies were used for double immunofluorescence. All monoclonal antibodies were purchased from Cedarlane Labs. Ltd. (Hornby, Canada) unless otherwise stated. All reagents were diluted and used as recommended.
Mitogen Assays.
Splenic T cell proliferative responses to Con A (Pharmacia) and B cell responses to LPS (Sigma Chemical Co., St. Louis, MO) were evaluated by [3H]thymidine incorporation, and quantitated on a beta counter (LKB Instrs., Uppsala Sweden) as previously described (32).
Histological Analysis.
The spleen and axillary and brachial LNs were carefully removed from each mouse and fixed in 4% formalin. The fixed tissues were embedded in paraffin, sectioned, stained with hematoxylin–eosin, and examined by light microscopy. The femurs from each mouse were decalcified before embedding and sectioning.
Direct Plaque-forming Cell Assay.
Mice were immunized with a single intravenous injection of 5 x 108 sheep red blood cells (SRBCs) in a volume of 0.3 ml. 4 d later, the direct splenic PFC response to SRBCs was assayed by the method of Cunningham and Szenberg (33) as modified previously (34).
Hematocrit Level.
Blood was collected from the retroorbital sinus of mice into two heparinized capillary tubes. The capillary tubes were centrifuged to determine the hematocrit.
BM Reconstitution Experiments.
BM transplantation were performed in 129/sv inbred mice to avoid the complications of allograft rejection and graft-versus-host disease (32, 34). Inbred mice were generated by mating 129/sv female mice with chimeric male mice which gave rise to germ line offsprings. Since the ES cells used were also 129/sv, all the resulting offsprings would therefore be of 129/sv background. 3-wk-old wt and 2-wk-old TC-PTP –/– recipients (129/sv strain) were exposed to 900 rads of
irradiation 18 h before a single intravenous injection of 1.5 x 107 wt (3-wk-old) or TC-PTP –/– (10–12 d old) BM cells. Irradiation controls received HBSS without BM cells.
| Results |
|---|
|
|
|---|
17-kb insert was isolated with four exons mapped as shown in Fig. 1 A. The four exons correspond to nc and aa numbers, respectively, of TC-PTP cDNA (14) as follows: nc 227–328/aa 54–88, nc 329–428/aa 88–121, nc 429– 561/aa 121–165, and nc 562–771/aa 166–235. The IHCSAGI domain is within the fourth exon of this 17-kb fragment. The relative intron positions within the PTPase domains of TC-PTP and other transmembrane protein tyrosine phosphatases were published by Charest et al. (23).
To inactivate the TC-PTP gene, a targeting vector was constructed that contained 5.5 kb of TC-PTP genomic sequences flanking the neo resistance gene, as depicted in Fig. 1 A. After proper homologous recombination events,
9 kb of genomic sequence, including 1.5 exons encoding aa 64–121 inclusively, were eliminated from the TC-PTP locus, in effect rendering the gene product enzymatically nonfunctional. Standard ES cell techniques using the J1 parental ES cell line, were used (see Materials and Methods) to generate ES cell lines harboring a heterozygously inactivated TC-PTP gene locus. Approximately 1,200 NEOr ES cell clones were tested by Southern analysis for proper recombination events. Seven clones were positive for the desired recombination event, as shown in Fig. 1 B by Southern analysis using a probe lying outside the targeting vector (probe A; Fig. 1 A) that hybridizes to a 5.2-kb NdeI fragment representing the wt locus and a 7.6-kb NdeI fragment representing the targeted locus. ES derived from two independent clones were used for blastocyst injections.
Lethality of TC-PTP Disrupted Gene.
Mating of TC-PTP +/– mice gave rise to offsprings that followed Mendelian frequencies suggesting that the TC-PTP +/– genotype was not lethal in utero (Fig. 1, C and F). Both ES targeted cell lines gave rise to identical phenotypes. Northern blot analysis of total RNA showed that TC-PTP message was present in +/+, but was completely absent in –/– mice (Fig. 1 D). Western blot analysis using the anti TC-PTP monoclonal antibody 3E2 demonstrated that in the homozygous animals, no full-length TC-PTP protein was detectable (Fig. 1 E). These results confirmed the proper targeting and generation of a null mutant for TC-PTP. All newborn mice appeared healthy and displayed no physical abnormalities. TC-PTP +/+ and +/– littermates remained healthy throughout the duration of the experiments (i.e., 9 mo). Thus, there was no apparent dose-dependent effect caused by inactivation of a single TC-PTP allele. By 2 wk of age, TC-PTP –/– animals showed a slight growth retardation, but were otherwise healthy. However, between 3–5 wk of age, all TC-PTP –/– animals developed hunched posture, progressive closure of the eyelids, decreased mobility, and diarrhea, and no TC-PTP –/– mice survived beyond 5 wk of age (Fig. 1 F).
Splenomegaly and Severe Anemia in TC-PTP –/– Mice.
To further investigate the phenotype of TC-PTP –/– mice, animals were killed at different days after birth. Gross anatomical observations indicated a striking splenomegaly and lymphadenopathy (data not shown) in mutant mice in the third week of life. The LNs of these mice showed loss of follicular demarcation due to hyperplasia of the follicles as a result of increased number of immunoblasts (data not shown). Hematocrit level of mutant mice decreased with increasing age, leading to severe anemia by day 21. Since the percentage of mature B cells was markedly increased in the LNs (Fig. 2 D), we tested the possibility that autoantibodies against erythrocytes were being produced and could therefore cause severe anemia. Using both flow cytometry and the Coomb's test (35), we failed to detect IgM autoantibodies in the circulation (data not shown). Histological analysis showed that, in the spleen of some TC-PTP –/– mice, the red pulp area was expanded (data not shown), consistent with increased sequestration of RBCs. These results suggest that the spleen of TC-PTP –/– mice could not compensate for the defective BM erythropoiesis leading to severe anemia that could contribute to the morbidity and mortality.
|
In contrast to the spleen and LNs, BM cellularity and the percentage of pre-B and mature B cell populations in the BM of mutant mice declined with age (Fig. 2, C and F). By day 21, there was at least a ninefold reduction in the absolute number of pre-B (0.4 x 106) and mature B (0.7 x 106) cells in the BM of TC-PTP –/– mice when compared to TC-PTP +/+ and +/– littermates. No significant differences were observed in the absolute number of B cell populations in the BM of TC-PTP +/+ and +/– littermates. Macrophage and granulocyte populations in the BM of TC-PTP –/– animals was not grossly altered (data not shown).
The thymus of TC-PTP –/– animals was involuted by day 21 owing to the marked decrease number of immature double positive (CD4+8+) thymocytes (Table 1). However, in both thymus and peripheral lymphoid organs, there was only a slight reduction of mature CD4+ and CD8+ thymocytes and the CD4+/CD8+ T cell ratio of TC-PTP –/– animals was similar to TC-PTP +/+ and +/– littermates (Table 1). These results suggest that lack of TC-PTP does not appear to affect the development of mature CD4+ and CD8+ T cells.
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Although B cell development in the BM was deficient in TC-PTP –/– mice (Fig. 2 F), T cells appeared to develop nearly normally (Table 1). The thymus of mutant mice underwent thymic involution as a result of a selective marked decrease in the number of CD4+8+ thymocytes; however, single positive CD4+ and CD8+ T cells, and CD4+/CD8+ ratio in the thymus, spleen, and LNs were similar to +/+ and +/– littermates (Table 1). These results suggest that phenotypic development of T cells is not markedly affected in the TC-PTP –/– mice. Despite a defect in B cell lymphopoiesis in the BM (Fig. 2, C and F), there was a marked increase in the number of pre-B and mature B cells in the LNs, and to a lesser degree in the spleen of TC-PTP –/– animals (Fig. 2, A, B, D, and E). The splenic changes are consistent with an expansion of the B cell compartment, as shown by the hyperplastic changes of the lymphoid follicles. The pattern of follicular expansion and the cytological features of the cells indicated that the proliferative changes represent lymphoid hyperplasia rather than lymphoma (data not shown). This implies that early B cell progenitors with limited renewal capacity migrate to the spleen, and in the absence of B cell production in the BM, these cells are able to renew the B cell population for a limited period of time but eventually die off as their renewal capacity is exhausted.
The disruption of the TC-PTP gene led to severe compromised in vitro T and B cell mitogenic responses and antibody production against SRBCs (Fig. 3). We also demonstrated that although hematopoiesis was restored in irradiated wt recipients injected with TC-PTP –/– BM, T and B cell mitogenic responses remained suppressed (Fig. 4 A). These results provide the first evidence that TC-PTP is important for the development of functional competence of T and B cells. The effector functions of T and B lymphocytes are mediated by critical intracellular tyrosine phosphorylation and dephosphorylation events. Engagement of the T and B cell receptor rapidly activates PTKs of the src and non-src families (36–38). In addition, both the phosphorylation of PTKs and their targeted proteins are regulated by PTPs. In T and B cells, the dephosphorylation activity of CD45, a receptor-like transmembrane glycoprotein, is crucial for T and B cell activation (10, 39, 40). There is now increasing evidence implicating a critical role of nonreceptor-like cytoplasmic PTPs in the signaling pathway of lymphocytes after receptor engagement (41– 43). Tailor et al. showed that SHP-2 participates actively in the activation of T cells (44), and Igarashi et al. demonstrated that a nonreceptor-like PTP is rapidly activated when B cell receptors are triggered (45). In light of these studies, it is possible that, since most TC-PTP is localized in the nucleus, it may provide further downstream modulation for lymphocyte activation. It is important to investigate the role of TC-PTP in lymphocyte activation and signaling, and these mice will provide us with the opportunity to carry out these studies.
The early normal erythropoiesis and lymphopoiesis followed by an almost total loss of these functions by 3–4 wk of age could be accounted for by the dramatic switch in hematopoiesis that occurs in different organs during mouse ontogeny. Primitive hematopoiesis occurs first in the yolk sac during embryonic development. By day 11 of fetal life, hematopoiesis is initiated in the fetal liver, presumably by the migration of hematopoietic stem cells from the yolk sac to the fetal liver which remains the main site of hematopoiesis during mid to late gestation. After day 15 of gestation, the fetal spleen also becomes an important hematopoietic organ and may remain functional for up to 2 wk of postnatal life. The BM initiates hematopoietic function during late fetal life and rapidly becomes the major site of hematopoiesis throughout life (46). It would appear that in the TC-PTP –/– animals, hematopoiesis may occur in a near normal fashion during fetal and early postnatal life (i.e., yolk sac, fetal liver, and spleen), but there is a failure in the BM to initiate hematopoietic function once it ceases in the fetal liver and the spleen. As a result there is an initial burst of hematopoiesis which is able to sustain the TC-PTP –/– animals for 2–3 wk. However, hematopoiesis declines in the fetal liver and spleen and it is not initiated in the BM, resulting in severe anemia and an arrest of B cell production in the marrow.
The precise reason for BM erythropoietic and B cell lymphopoietic failure is unknown. The inability of wt BM to rescue irradiated and nonirradiated TC-PTP –/– recipients strongly suggests that the BM microenvironment of the mutant mice is defective (Table 2). In support of this possibility, we demonstrated that the BM of TC-PTP –/– mice was able to rescue and restore hematopoiesis in irradiated wt recipients (Table 2). These results indicate that the mutant BM contains stem cells that can differentiate in a normal microenvironment. Although we have not yet identified the exact defect(s) in the BM microenvironment of TC-PTP –/– mice, several possibilities may exist. Histological analysis of the BM showed that the number of BM stromal cells of TC-PTP –/– animals were considerably reduced when compared to wt controls (Fig. 5). It has been well documented that the interaction of hematopoietic precursor cells with BM stromal cells is crucial for proper development and functions of the different hematopoietic cell lineages (47). Hence, the deficient number of BM stromal cells in mutant mice could likely affect the integrity of the BM microenvironment which consequently could lead to impaired B cell lymphopoiesis and erythropoiesis.
A second possibility is that the reduced number of remaining stromal cells fail to function properly. The adhesive interactions, via adhesion molecules, between progenitor cells and BM stromal cells and the extracellular matrix are also critical for hematopoiesis (47–50). Recently, a report has implicated the critical role of
4 integrins in maintaining B cell lymphopoiesis in the BM since the disruption of the
4 gene by homologous recombination resulted in severe impairment of B cell lymphopoiesis (51). However,
4 integrins did not appear to be important during fetal and early postnatal hematopoiesis, but were critical for adult hematopoiesis, a phenomenon similar to the one that we observed in the TC-PTP –/– mice.
A third explanation for the defective hematopoiesis in TC-PTP –/– mice may be that cytokines produced by the BM microenvironment are inadequate. In vivo studies have shown that B cell lymphopoiesis markedly depends on the secretion of IL-7 by BM stromal cells (52). Similarly, IL-11 and -3, secreted by BM stromal cells, have been demonstrated to be potent stimulators of erythropoiesis (53). Thus, TC-PTP may be involved in the production of IL-3, -7, -11, and/or other hematopoietic cytokines. Alternatively, TC-PTP may be directly implicated in signaling pathways of the stromal cells. Jarvis and LeBien reported that direct contact of B cell precursors with BM stromal cells induced tyrosine phosphorylation of various proteins in the stromal cells (54). The induction of tyrosine kinases in the stromal cells may ultimately regulate expression of specific genes, such as cytokines and adhesion molecules, that are important for hematopoiesis. The exact defect(s) in BM microenvironment and lymphoid function in TC-PTP –/– mice has not been identified, however these animals provide us with an excellent model to answer these important questions.
| Acknowledgments |
|---|
Submitted: 17 April 1997
Revised: 20 June 1997
1 Abbreviations used in this paper: aa, amino acid; BM, bone marrow; ES, embryonic stem; nc, nucleotide; neo, neomycin; PFC, plaque-forming cell; PTP, protein tyrosine phosphatase; PTK, protein tyrosine kinase; SRBC, sheep RBC; TC-PTP, T cell PTP.
| References |
|---|
|
|
|---|
1 Funk PE, Kincade PW & Witte PL. Native associations of early hematopoietic stem cells and stromal cells isolated in bone marrow cell aggregates, Blood, 1994, 83, 361–369.
2 Anderson SJ & Perlmutter RM. A signalling pathway governing early thymocyte maturation, Immunol Today, 1995, 16, 99–105.[Medline]
3 Satterthwaite A & Witte O. Genetic analysis of tyrosine kinase funtion in B cell development, Annu Rev Immunol, 1996, 14, 131–154.[Medline]
4 Hardin JD, Boast S, Schwartzberg PL, Lee G, Alt FW, Stall AM & Goff SP. Abnormal peripheral lymphocyte function in c-abl mutant mice, Cell Immunol, 1996, 172, 100–172.[Medline]
5 Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, Harbison ML, Robertson EJ & Goff SP. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations, Cell, 1991, 65, 1165–1175.[Medline]
6 Tybulewicz VLJ, Crawford CE, Jackson PK, Bronson RT & Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene, Cell, 1991, 65, 1153–1163.[Medline]
7 Trowbridge IS & Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development, Annu Rev Immunol, 1994, 12, 85–116.[Medline]
8 Yakura H. The role of protein tyrosine phosphatases in lymphocyte activation and differentiation, Crit Rev Immunol, 1994, 14, 311–336.[Medline]
9 Byth KF, Conroy LA, Howlett S, Smith AJ, May J, Alexander DR & Holmes N. CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+thymocytes, and B cell maturation, J Exp Med, 1996, 183, 1707–1718.
10 Hurley TR, Hyman R & Sefton BM. Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck, fyn and c-srctyrosine protein kinases, Mol Cell Biol, 1993, 13, 1651–1656.
11 Tsui HW, Siminovitch KA, de Souza L & Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene, Nat Genet, 1993, 4, 124–129.[Medline]
12 Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, Matthews RJ, Thomas ML & Beier DR. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene, Cell, 1993, 73, 1445–1454.[Medline]
13 Cool DE, Tonks NK, Charbonneau H, Walsh KA, Fischer EH & Krebs EG. cDNA isolation from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family, Proc Natl Acad Sci USA, 1989, 86, 5257–5261.
14 Mosinger B, Tillmann U, Westphal H & Tremblay ML. Cloning and characterization of a mouse cDNA encoding a cytoplasmic protein-tyrosine-phosphatase, Proc Natl Acad Sci USA, 1992, 89, 499–503.
15 Champion-Arnaud P, Gesnel M-C, Foulkes N, Ronsin C, Sassone-Corsi P & Breathnach R. Activation of transcription via AP-1 or CREB regulatory sites is blocked by protein tyrosine phosphatases, Oncogene, 1991, 6, 1203–1209.[Medline]
16 Kamatkar S, Radha V, Nambirajan S, Reddy R-S & Swarup G. Two splice variants of a tyrosine phosphatase differ in substrate specificity, DNA binding, and subcellular location, J Biol Chem, 1996, 271, 26755–26761.
17 Lorenzen JA, Dadabay CY & Fischer EH. COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus, J Cell Biol, 1995, 131, 631–643.
18 Tillman U, Wagner J, Boerboom D, Westphal H & Tremblay ML. Nuclear localization and cell cycle regulation of a murine protein tyrosine phosphatase, Mol Cell Biol, 1994, 14, 3030–3040.
19 Faure R & Posner BI. Differential intracellular compartmentalization of phosphotyrosine phosphatases in a glial cell line: TC-PTP versus PTP-1B, GLIA, 1993, 9, 311–314.[Medline]
20 Cool DE, Tonks NK, Charbonneau H, Fischer EH & Krebs EG. Expression of a human T-cell protein tyrosine-phosphatase in baby hamster kidney cells, Proc Natl Acad Sci USA, 1990, 87, 7280–7284.
21 Zander NF, Lorenzen JA, Cool DE, Tonks NK, Daum G, Krebs EG & Fischer EH. Purification and characterization of a human recombinant T-cell protein-tyrosine-phosphatase from a baculovirus expression system, Biochemistry, 1991, 30, 6964–6970.[Medline]
22 Gould KL, Moreno S, Tonks NK & Nurse P. Complementation of the mitotic activator, p80cdc25, by a human protein-tyrosine phosphatase, Science (Wash DC), 1990, 250, 1573–1575.
23 Charest A, Wagner J, Muise ES, Heng HHQ & Tremblay ML. Structure of the murine MPTP-PEST gene: genomic organization and chromosomal mapping, Genomics, 1995, 28, 501–507.[Medline]
24 Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 1.40–1.41.
25 Love PE, Tremblay ML & Westphal H. Targeting of the T-cell receptor
-chain gene in embryonic stem cells: strategies for generating multiple mutations in a single gene, Proc Natl Acad Sci USA, 1992, 89, 9929–9933.
26 Vidal S, Tremblay ML, Govoni G, Gauthier S, Sebastiani G, Malo D, Skamene E, Olivier M, Jothy S & Gros P. The Ity/Lsh/Bcglocus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene, J Exp Med, 1995, 182, 655–666.
27 Li E, Bestor TH & Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality, Cell, 1992, 69, 915–926.[Medline]
28 Ramírez-Solis, R., A.C. Davis, and A. Bradley. 1993. Methods in Enzymology. Vol. 225. Guide to Techniques in Mouse Development. P.M. Wassarman and M.C. DePamphilis, editors. Academic Press, San Diego. 855–878.
29 Church GM & Gilbert W. Genomic sequencing, Proc Natl Acad Sci USA, 1984, 81, 1991–1995.
30 Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples, Biotechniques, 1993, 15, 532–534.[Medline]
31 Piechaczyk M, Blanchard JM, Marty L, Dani C, Panabieres F, El S, Sabouty, Fort P & Jeanteur P. Post-transcriptional regulation of glyceraldehyde-3-phosphate-dehydrogenase gene expression in rat tissues, Nucleic Acids Res, 1984, 12, 6951–6963.
32 You-Ten KE, Seemayer TA, Wisse B, Bertley FMN & Lapp WS. Induction of a glucocorticoid-sensitive F1-antiparental mechanism that affects engraftment during graft-versus-host disease, J Immunol, 1995, 155, 172–180.[Abstract]
33 Cunningham AJ & Szenberg A. Further improvements in the plaque technique for detecting single antibody-forming cells, Immunology, 1968, 14, 599–600.[Medline]
34 Kornbluth M, You-Ten E, Desbarats J, Gamache S, Xenocostas A & Lapp WS. T cell subsets in the thymus of graft-versus-host immunosuppressed mice, Transplantation (Baltimore), 1991, 51, 262–267.[Medline]
35 Baxter AG & Mandel TE. Hemolytic anemia in non-obese diabetic mice, Eur J Immunol, 1991, 21, 2051–2055.[Medline]
36 Mustelin T. T cell antigen receptor signaling: three families of tyrosine kinases and a phosphatase, Immunity, 1994, 1, 351–356.[Medline]
37 Burkhardt AL, Brunswick M, Bolen JB & Mond JJ. Anti-immunoglobulin stimulation of B lymphocytes activates src-related protein-tyrosine kinases, Proc Natl Acad Sci USA, 1991, 88, 7410–7414.
38 Yamanashi Y, Kakiuchi T, Mizuguchi J, Yamamoto T & Toyoshima K. Association of B cell antigen receptor with protein tyrosine kinase Lyn, Science (Wash DC), 1991, 251, 192–194.
39 Cahir McFarland, E.D., T.R. Hurley, J.T. Pingel, B.M. Sefton, A. Shaw, and M.L. Thomas. Correlation between Src family member regulation by the protein-tyrosine-phosphatase CD45 and transmembrane signaling through the T cell receptor, Proc Natl Acad Sci USA, 1993, 90, 1402–1406.
40 Justement LB, Brown VK & Lin J. Regulation of B-cell activation by CD45: a question of mechanism, Immunol Today, 1994, 15, 399–406.[Medline]
41 D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA & Cambier JC. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by FcRIIB1, Science (Wash DC), 1995, 268, 293–297.
42 Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS & Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4, Science (Wash DC), 1996, 272, 1170–1173.[Abstract]
43 Shen S-H, Bastien L, Posner BI & Chrétien P. A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases, Nature (Lond), 1991, 352, 736–739.[Medline]
44 Tailor P, Jascur T, Williams S, Von Willebrand M, Couture C & Mustelin T. Involvement of Src-homology-2-domain–containing protein-tyrosine phosphatase 2 in T cell activation, Eur J Biochem, 1996, 237, 736–742.[Medline]
45 Igarashi H, Kuwahara K, Nomura J, Matsuda A, Kikuchi K, Inui S & Sakaguchi N. B cell Ag receptor mediates different types of signals in the protein kinase activity between immature B cell and mature B cell, J Immunol, 1994, 153, 2381–2393.[Abstract]
46 Ikuta K, Uchida N, Friedman J & Weissmann IL. , Annu Rev Immunol, 1992, 10, 759–783.[Medline]
47 Dorshkind K. Regulation of hemopoiesis by bone marrow stromal cells and their products, Annu Rev Immunol, 1990, 8, 111–137.[Medline]
48 Williams DA, Rios M, Stephens C & Patel VP. Fibronectin and VLA-4 in hematopoietic stem cell–microenvironment interactions, Nature (Lond), 1991, 352, 438–441.[Medline]
49 Jacobsen K & Osmond DG. Microenvironmental organization and stromal cell association of B lymphocyte precursor cells in mouse bone marrow, Eur J Immunol, 1990, 20, 2395–2404.[Medline]
50 Jacobsen K, Miyake K, Kincade PW & Osmond DG. Highly restricted expression of a stromal cell determinant in mouse bone marrow in vivo, J Exp Med, 1992, 176, 927–935.
51 Arroyo AG, Yang JT, Rayburn H & Hynes RO. Differential requirements for
-integrins during fetal and adult hematopoiesis, Cell, 1996, 85, 997–1008.[Medline]
52 Grabstein KH, Waldschmidt TJ, Finkelman FD, Hess BW, Alpert AR, Boiani NE, Namen AE & Morissey PJ. Inhibition of murine B and T lymphopoiesis in vivo by an anti–interleukin 7 monoclonal antibody, J Exp Med, 1993, 178, 257–264.
53 Quesniaux VFJ, Clark SC, Turner K & Fagg B. Interleukin-11 stimulates multiple phases of erythropoiesis in vitro, Blood, 1992, 80, 1218–1223.
54 Jarvis LJ & LeBien TW. Stimulation of human bone marrow stromal cell tyrosine kinases and IL-6 production by contact with B lymphocytes, J Immunol, 1995, 155, 2359–2368.[Abstract]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|